Back to Search
Start Over
FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
- Source :
- Business Wire. October 24, 2024
- Publication Year :
- 2024
-
Abstract
- -- Phase 3 Studies on the Horizon in both PNH and C3G -- SEATTLE -- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.813403072